Safety and efficacy of anticoagulation with low-molecular-weight heparin in patients with intracerebral hemorrhage: a meta-analysis

doi:10.3760/cma.j.issn.1007-1245.2023.09.007

Abstract

Abstract:

Objective　To evaluate the safety and efficacy of anticoagulation with low molecular weight heparin in patients with intracerebral hemorrhage (ICH). Methods　Clinical trials related to anticoagulation with low molecular weight heparin in patients with ICH were collected by searching PubMed, China National Knowledge Infrastructure (CNKI), and Wanfang databases. The deadline of retrieval period was October 16, 2022. After judging the heterogeneity by χ² test, a meta-analysis was performed on the collected clinical trials using RevMan 5.4. Results　The meta-analysis results showed that there was no statistically significant difference in the incidence of rebleeding between the patients with ICH treated with low molecular weight heparin and the control group [RR=0.97 (0.55, 1.73)], the risk of deep vein thrombosis (DVT) was significantly reduced compared with that in the control group [RR=0.22 (0.14, 0.33)], and the risk of pulmonary embolism (PE) was also significantly reduced compared with that in the control group [RR=0.24 (0.08, 0.68)]. Conclusion　It is safe and effective to use low-molecular-weight heparin in the prevention of thrombosis in patients with ICH.

Key words:

Low-molecular-weight heparin, Intracerebral hemorrhage, Meta-analysis

摘要：

目的　评估对脑出血患者使用低分子肝素抗凝的安全性及有效性。方法　通过检索PubMed、中国知网（CNKI）及万方数据库，搜集脑出血患者使用低分子肝素抗凝相关的临床试验。检索时间为建库至2022年10月16日。经χ²检验判断异质性后，采用RevMan 5.4对搜集到的临床试验进行meta分析。结果　meta分析结果显示，对于脑出血患者使用低分子肝素，其再出血的发生率与对照组比较差异无统计学意义［RR=0.97（0.55，1.73）］，其发生深静脉血栓形成（DVT）的风险较对照组明显降低［RR=0.22（0.14，0.33）］，其发生肺动脉栓塞（PE）的风险也较对照组明显降低［RR=0.24（0.08，0.68）］。结论　对脑出血患者使用低分子肝素抗凝治疗在预防血栓形成上是安全且有效的。

关键词:

低分子肝素, 脑出血, meta分析

Xu Yucheng, Yuan Lijuan, Fu Xiaoyu, Mao Liantao, Zhang Zhiqiang.

Safety and efficacy of anticoagulation with low-molecular-weight heparin in patients with intracerebral hemorrhage: a meta-analysis [J]. International Medicine and Health Guidance News, 2023, 29(9): 1208-1213.

徐煜城袁丽娟付晓宇毛连涛张志强.

脑出血患者使用低分子肝素抗凝治疗的安全性及有效性的meta分析 [J]. 国际医药卫生导报, 2023, 29(9): 1208-1213.

References

[1] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组.中国脑出血诊治指南(2019)[J].中华神经科杂志,2019,52(12):994-1005. DOI:10.3760/cma.j.issn.1006- 7876.2019.12.003.
[2] 孟苗苗,倪小佳,林浩,等.脑卒中临床实践指南推荐意见的系统评价[J].中国循证心血管医学杂志,2022,14(7):780-784. DOI:10.3969/j.issn.1674-4055.2022.07.03.
[3] 杨楠,宋海庆,吉训明,等.2022年版美国心脏协会/美国卒中协会自发性脑出血患者管理指南更新要点及解读[J].中国脑血管病杂志,2022,19(11):729-732,748. DOI:10.3969/j.issn.1672-5921.2022.11.001.
[4] 俞斌.下肢深静脉血栓的诊断及治疗进展[J].中国骨与关节损伤杂志,2017,32(1):109-111. DOI:10.7531/j.issn.1672- 9935.2017.01.041.
[5] Li J, Wang D, Wang W, et al. In-hospital venous thromboembolism is associated with poor outcome in patients with spontaneous intracerebral hemorrhage: a multicenter, prospective study[J]. J Stroke Cerebrovasc Dis, 2020, 29(8):104958. DOI: 10.1016/j.jstrokecerebrovasdis.2020.104958.
[6] 刘慧轩,何雅军.血清胸苷激酶1对甲状腺癌诊断价值的meta分析[J].国际医药卫生导报,2022,28(3):357-360. DOI:10.3760/cma.j.issn.1007-1245.2022.03.015.
[7] 杨汉,顾玉兰.神经纤毛蛋白-1在胃癌组织中的表达与临床病理特征及预后相关性的meta分析[J].国际医药卫生导报,2022,28(22):3246-3251. DOI:10.3760/cma.j.issn.1007-1245.2022.22.031.
[8] Tetri S, Hakala J, Juvela S, et al. Safety of low-dose subcutaneous enoxaparin for the prevention of venous thromboembolism after primary intracerebral haemorrhage[J]. Thromb Res, 2008, 123(2):206-212. DOI: 10.1016/j.thromres.2008.01.018.
[9] 冯景,张晓丽.低分子肝素钙预防脑出血术后下肢深静脉血栓的效果及对凝血指标的影响[J].中外医学研究,2021,19(8):25-27. DOI:10.14033/j.cnki.cfmr.2021.08.009.
[10] 李爱静,刘海华.低分子肝素钙注射液预防高血压脑出血术后患者下肢深静脉血栓形成的疗效和安全性探讨[J].中风与神经疾病杂志,2011,28(3):253-254. DOI:10.19845/j.cnki.zfysjjbzz.2011.03.016
[11] 王茜.早期应用低分子肝素对重症脑出血患者的效果评价[J].中国现代药物应用,2022,16(11):84-86. DOI:10.14164/j.cnki.cn11-5581/r.2022.11.028.
[12] 王涛.血栓弹力图指导下应用低分子肝素钙预防高血压脑出血术后 DVT 效果观察[J].山东医药,2015,55(32):46-47. DOI:10.3969/j.issn.1002-266X.2015.32.018.
[13] 吴华勇,蒋冰洁,戴伟民.低分子肝素对自发性脑实质内出血术后下肢深静脉血栓形成的预防价值[J].中华急诊医学杂志,2022,31(8):1131-1134. DOI:10.3760/cma.j.issn.1671-0282.2022.08.021.
[14] 许鹏,张军,黄妍,等.研究早期康复干预联合低分子肝素对脑出血患者深静脉血栓形成的预防作用[J/CD].世界最新医学信息文摘(连续型电子期刊),2019,19(A2):113,115. DOI:10.19613/j.cnki.1671-3141.2019.102.067.
[15] 羊飞龙,许伍环.气压治疗联合低分子肝素预防高血压脑出血术后深静脉血栓的临床评价[J/CD].世界最新医学信息文摘(连续型电子期刊),2018,18(4):22-23,26. DOI:10.19613/j.cnki.1671-3141.2018.04.010.
[16] 杨明,夏志民.应用低分子肝素钙预防高血压脑出血术后深静脉血栓的临床研究[J].中国社区医师(医学专业),2010,12(26):32-32. DOI:10.3969/j.issn.1007- 614x.2010.26.032.
[17] 尹丽鹤,刘秋武,董延慧.分析低分子肝素钙对脑出血下肢深静脉血栓的预防作用[J].中国继续医学教育,2019,11(5):109-111. DOI:10.3969/j.issn.1674-9308.2019.05.047.
[18] 于红春,杨伟,苏莉.低剂量低分子肝素钠预防脑出血患者下肢深静脉血栓形成临床体会[J].脑与神经疾病杂志,2015,23(4):299-301.
[19] 张焕.早期低分子肝素应用预防脑出血患者下肢深静脉血栓的疗效观察[J].现代实用医学,2017,29(12):1563-1564. DOI:10.3969/j.issn.1671-0800.2017.12.009.
[20] 赵俊霞,刘颖超.低分子肝素钙对脑出血下肢深静脉血栓形成的预防效果[J].深圳中西医结合杂志,2020,30(14):187-188. DOI:10.16458/j.cnki.1007-0893.2020.14.096.
[21] Chu Q, Liao L, Wei W, et al. Venous thromboembolism in ICU patients with intracerebral hemorrhage: risk factors and the prognosis after anticoagulation therapy[J]. Int J Gen Med, 2021, 14:5397-5404. DOI: 10.2147/IJGM.S327676.
[22] Eck RJ, Hulshof L, Wiersema R, et al. Incidence, prognostic factors, and outcomes of venous thromboembolism in critically ill patients: data from two prospective cohort studies[J]. Crit Care, 2021, 25(1):27. DOI: 10.1186/s13054-021-03457-0.
[23] Goldstein JN, Fazen LE, Wendell L, et al. Risk of thromboembolism following acute intracerebral hemorrhage[J]. Neurocrit Care, 2009, 10(1):28-34. DOI: 10.1007/s12028-008-9134-3.
[24] Lansberg MG, O'Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J]. Chest, 2012, 141(2 Suppl):e601S-e636S. DOI: 10.1378/chest.11-2302.
[25] Chibbaro S, Cebula H, Todeschi J, et al. Evolution of prophylaxis protocols for venous thromboembolism in neurosurgery: results from a prospective comparative study on low-molecular-weight heparin, elastic stockings, and intermittent pneumatic compression devices[J]. World Neurosurg, 2018, 109:e510-e516. DOI: 10.1016/j.wneu.2017.10.012.
[26] 陈希妍,张建新,牛丽丹,等.氯吡格雷联合低分子肝素对老年心肌梗死患者血清血脂及炎性因子的影响[J].广州医药,2021,52(2):46-49. DOI:10.3969/j.issn.1000-8535.2021. 02.010.